Jessica A Couch
Overview
Explore the profile of Jessica A Couch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katz J, Rothstein J, Cudkowicz M, Genge A, Oskarsson B, Hains A, et al.
Ann Clin Transl Neurol
. 2022 Jan;
9(1):50-66.
PMID: 35014217
Objective: Dual leucine zipper kinase (DLK), which regulates the c-Jun N-terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral...
2.
Ayalon G, Lee S, Adolfsson O, Foo-Atkins C, Atwal J, Blendstrup M, et al.
Sci Transl Med
. 2021 May;
13(593).
PMID: 33980574
Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better...
3.
Mandikian D, Figueroa I, Oldendorp A, Rafidi H, Ulufatu S, Schweiger M, et al.
AAPS J
. 2018 Oct;
20(6):107.
PMID: 30298434
We previously performed a comparative assessment of tissue-level vascular physiological parameters in mice and rats, two of the most commonly utilized species in translational drug development. The present work extends...
4.
Bumbaca Yadav D, Maloney J, Wildsmith K, Fuji R, Meilandt W, Solanoy H, et al.
Br J Pharmacol
. 2017 Sep;
174(22):4173-4185.
PMID: 28859225
Background And Purpose: The potential for therapeutic antibody treatment of neurological diseases is limited by poor penetration across the blood-brain barrier. I.c.v. delivery is a promising route to the brain;...
5.
Lo M, Kim H, Tong R, Bainbridge T, Vernes J, Zhang Y, et al.
J Biol Chem
. 2017 Jan;
292(9):3900-3908.
PMID: 28077575
The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a therapeutic context, however, the cytotoxic effector function of an antibody is often not desirable and can create...
6.
Ruppel J, Brady A, Elliott R, Leddy C, Palencia M, Coleman D, et al.
J Immunol Res
. 2016 Jul;
2016:2921758.
PMID: 27413757
Anti-therapeutic antibodies (ATAs) may impact drug exposure and activity and induce immune complex mediated toxicity; therefore the accurate measurement of ATA is important for the analysis of drug safety and...
7.
Gadkar K, Bumbaca Yadav D, Zuchero J, Couch J, Kanodia J, Kenrick M, et al.
Eur J Pharm Biopharm
. 2016 Jan;
101:53-61.
PMID: 26820920
Treatment of diseases of the central nervous system by monoclonal antibodies may be limited by the restricted uptake of antibodies across the blood-brain barrier (BBB). An antibody targeting transferrin receptor...
8.
Couch J, Zhang G, Beyer J, Zuch de Zafra C, Gupta P, Kamath A, et al.
Clin Cancer Res
. 2015 Nov;
22(6):1469-79.
PMID: 26589434
Purpose: Although agents targeting Delta-like ligand 4 (DLL4) have shown great promise for angiogenesis-based cancer therapy, findings in recent studies have raised serious safety concerns. To further evaluate the potential...
9.
Yu Y, Atwal J, Zhang Y, Tong R, Wildsmith K, Tan C, et al.
Sci Transl Med
. 2014 Nov;
6(261):261ra154.
PMID: 25378646
Using therapeutic antibodies that need to cross the blood-brain barrier (BBB) to treat neurological disease is a difficult challenge. We have shown that bispecific antibodies with optimized binding to the...
10.
Couch J, Yu Y, Zhang Y, Tarrant J, Fuji R, Meilandt W, et al.
Sci Transl Med
. 2013 May;
5(183):183ra57, 1-12.
PMID: 23636093
Bispecific antibodies using the transferrin receptor (TfR) have shown promise for boosting antibody uptake in brain. Nevertheless, there are limited data on the therapeutic properties including safety liabilities that will...